Sarepta Therapeutics (SRPT) to Release Quarterly Earnings on Monday

Sarepta Therapeutics (NASDAQ:SRPT) is expected to issue its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of $0.02 per share and revenue of $331.51 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The firm had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. During the same quarter in the previous year, the firm earned $0.07 EPS. The company’s quarterly revenue was up 68.4% compared to the same quarter last year. On average, analysts expect Sarepta Therapeutics to post $3 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Sarepta Therapeutics Stock Up 3.3%

Shares of Sarepta Therapeutics stock opened at $24.01 on Friday. The firm’s 50 day moving average price is $20.23 and its 200-day moving average price is $27.13. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a market cap of $2.35 billion, a P/E ratio of -27.60 and a beta of 0.51.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of analyst reports. Morgan Stanley lifted their price objective on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 29th. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and set a $22.00 price objective on the stock in a research report on Tuesday, July 29th. Mizuho reaffirmed a “neutral” rating and issued a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Piper Sandler boosted their target price on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, August 25th. Eight research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus target price of $34.50.

Institutional Trading of Sarepta Therapeutics

Several large investors have recently made changes to their positions in SRPT. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 214.2% in the 1st quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 3,671 shares during the last quarter. Great Lakes Advisors LLC purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at $224,000. Guggenheim Capital LLC boosted its holdings in shares of Sarepta Therapeutics by 33.5% in the 2nd quarter. Guggenheim Capital LLC now owns 45,790 shares of the biotechnology company’s stock valued at $783,000 after acquiring an additional 11,497 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Sarepta Therapeutics by 59.2% in the 2nd quarter. First Trust Advisors LP now owns 627,561 shares of the biotechnology company’s stock valued at $10,731,000 after acquiring an additional 233,391 shares during the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Sarepta Therapeutics by 7.1% in the 2nd quarter. California Public Employees Retirement System now owns 115,340 shares of the biotechnology company’s stock valued at $1,972,000 after acquiring an additional 7,665 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.